OptiNose (OptiNose) GF Value Rank : 8 (As of Apr. 27, 2024)

View and export this data going back to 2017. Start your Free Trial

What is OptiNose GF Value Rank?

OptiNose has the GF Value Rank of 8.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Competitive Comparison of OptiNose's GF Value Rank

For the Drug Manufacturers - Specialty & Generic subindustry, OptiNose's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OptiNose's GF Value Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, OptiNose's GF Value Rank distribution charts can be found below:

* The bar in red indicates where OptiNose's GF Value Rank falls into.

OptiNose GF Value Rank Related Terms

Thank you for viewing the detailed overview of OptiNose's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

OptiNose (OptiNose) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OptiNose Inc (NAS:OPTN) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

0OP:Germany

Address

1020 Stony Hill Road, Suite 300, Yardley, PA, USA, 19067

Website

https://www.optinose.com

OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.

Executives

Marino Michael F Iii	officer: Chief Legal Officer & Corp Sec	C/O NUPATHE, INC., 227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Ramy A Mahmoud	officer: President & COO	1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Peter K Miller	director, officer: Chief Executive Officer	C/O INTERNET CAPITAL GROUP, 690 LEE ROAD, SUITE 310, WAYNE PA 19087
Mvm Partners, Llc	10 percent owner	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Michele Janis	officer: Acting Chief Financial Officer	1020 STONY HILL ROAD, YARDLEY PA 19067
Victor M Clavelli	officer: Chief Commercial Officer	1020 STONY HILL ROAD, SUITE 300, YARDLEY PA 19067
Paul Jr. Spence	officer: Chief Commercial Officer	1507 POWNAL DRIVE, YARDLEY PA 19067
Anthony J Krick	officer: Chief Accounting Officer	1020 STONY HILL ROAD, YARDLEY PA 19067
R John Fletcher	director	C/O VYANT BIO, INC., 201 ROUTE 17 NORTH, 2ND FLOOR, RUTHERFORD NJ 07070
Kyle Dempsey	director	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Eric Bednarski	director	OLD CITY HALL, 45 SCHOOL STREET, BOSTON MA 02108
Partners Llp Mvm	10 percent owner	30 ST. GEORGE STREET, LONDON X0 W1S SFH
Keith A. Goldan	officer: Chief Financial Officer	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Joseph C Scodari	director	JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK NJ 08933
Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080